Suchen
Halozyme Therapeutics Inc
HALOZur Watchlist hinzufügen
112.450USD
+2.770+2.53%
Handelsschluss 09-18 16:00（ET）
12.84BMarktkapitalisierung
38.10KGV TTM
Halozyme Therapeutics Inc (HALO) Umsatzentwicklung
Aktualisiert: Jun 30, 2026Im vergangenen Jahr erzielte Halozyme Therapeutics Inc für sein leistungsstärkstes Segment, Royalties, Einnahmen von 867.84M USD. Die Region United States leistete den größten Beitrag mit 822.98M USD im letzten Jahr.
Nach Geschäftsbereich
Umsatz
Anteil
Jährlich
Jährlich
Vierteljährlich
Royalties
Sales of proprietary products
Sales of bulk rHuPH20
Sales-based milestones
Sales of device partnered products
Event-based development and regulatory milestones and other fees
Upfront license fees
Device Licensing and development revenue
ENHANZE
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Royalties
867.84M(62.14%)
570.99M(56.24%)
447.87M(54.01%)
360.48M(54.61%)
203.90M(45.99%)
88.60M(33.11%)
69.90M(35.66%)
Sales of proprietary products
194.61M(13.93%)
166.62M(16.41%)
130.83M(15.78%)
72.85M(11.04%)
23.26M(5.25%)
17.03M(6.36%)
17.00M(8.67%)
Sales of bulk rHuPH20
133.02M(9.52%)
86.33M(8.50%)
115.44M(13.92%)
82.08M(12.43%)
80.96M(18.26%)
38.24M(14.29%)
48.28M(24.64%)
Sales-based milestones
70.00M(5.01%)
30.00M(2.95%)
--(--)
10.00M(1.51%)
50.00M(11.28%)
15.00M(5.61%)
--(--)
Sales of device partnered products
48.81M(3.50%)
50.54M(4.98%)
54.58M(6.58%)
36.10M(5.47%)
--(--)
--(--)
--(--)
Event-based development and regulatory milestones and other fees
47.00M(3.37%)
72.50M(7.14%)
69.00M(8.32%)
59.00M(8.94%)
42.00M(9.47%)
69.50M(25.97%)
5.50M(2.81%)
Upfront license fees
18.47M(1.32%)
27.00M(2.66%)
2.00M(0.24%)
30.00M(4.54%)
42.00M(9.47%)
37.26M(13.93%)
53.00M(27.04%)
Device Licensing and development revenue
16.86M(1.21%)
11.34M(1.12%)
9.53M(1.15%)
9.61M(1.46%)
1.19M(0.27%)
1.25M(0.47%)
1.54M(0.79%)
ENHANZE
--(--)
--(--)
--(--)
--(--)
--(--)
719.00K(0.27%)
768.00K(0.39%)
Nach Region
Umsatz
Anteil
Jährlich
Jährlich
Vierteljährlich
United States
Switzerland
Belgium
Japan
All other foreign
United States
Switzerland
Belgium
Ireland
FY2025
FY2024
FY2023
FY2022
United States
822.98M(58.93%)
--(--)
--(--)
--(--)
Switzerland
276.41M(19.79%)
--(--)
--(--)
--(--)
Belgium
217.52M(15.57%)
--(--)
--(--)
--(--)
Japan
46.37M(3.32%)
18.94M(1.87%)
15.10M(1.82%)
47.94M(7.26%)
All other foreign
33.33M(2.39%)
9.53M(0.94%)
19.58M(2.36%)
5.26M(0.80%)
United States
--(--)
690.46M(68.00%)
587.20M(70.81%)
437.99M(66.35%)
Switzerland
--(--)
212.39M(20.92%)
149.02M(17.97%)
166.84M(25.27%)
Belgium
--(--)
84.00M(8.27%)
58.35M(7.04%)
2.09M(0.32%)
Ireland
--(--)
--(--)
--(--)
3.00K(--)